Effects of hypogonadism on bone metabolism in female adolescents and young adults

Nature Reviews Endocrinology

Volumn 8, Issue 7, 2012, Pages 395-404

  Misra, Madhusmita ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ESTROGEN; ETHINYLESTRADIOL; GROWTH HORMONE; PROGESTERONE; SOMATOMEDIN C; TESTOSTERONE; VITAMIN D;

ADOLESCENT; ADULT; AMENORRHEA; ANOREXIA NERVOSA; BODY MASS; BODY WEIGHT; BONE METABOLISM; CALCIUM DEFICIENCY; EXERCISE; FEMALE; HUMAN; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; PRIORITY JOURNAL; REVIEW; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; BONE AND BONES; BONE DENSITY; FEMALE; HUMANS; HYPOGONADISM; INSULIN-LIKE GROWTH FACTOR I; YOUNG ADULT;

EID: 84862504803     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.238     Document Type: Review

References (145)

1. Ackerman, K. E. et al. Bone microarchitecture is impaired in adolescent amenorrheic athletes compared with eumenorrheic athletes and nonathletic controls. J. Clin. Endocrinol. Metab. 96, 3123-3133 (2011).
2. Walsh, C. J. et al. Women with anorexia nervosa: finite element and trabecular structure analysis by using flat-panel volume CT. Radiology 257, 167-174 (2010).
3. Stein, E. M. et al. Abnormal microarchitecture and reduced stiffness at the radius and tibia in postmenopausal women with fractures. J. Bone Miner. Res. 25, 2572-2581 (2010).
4. Sornay-Rendu, E., Boutroy, S., Munoz, F. & Delmas, P. D. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J. Bone Miner. Res. 22, 425-433 (2007).
5. Misra, M. et al. Effects of anorexia nervosa on clinical, hematologic, biochemical, and bone density parameters in community-dwelling adolescent girls. Pediatrics 114, 1574-1583 (2004).
6. Ohlsson, C., Bengtsson, B. A., Isaksson, O. G., Andreassen, T. T. & Slootweg, M. C. Growth hormone and bone. Endocr. Rev. 19, 55-79 (1998).
7. Rauch, F. Bone accrual in children: adding substance to surfaces. Pediatrics 119 (Suppl. 2), S137-S140 (2007).
8. Theintz, G. et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J. Clin. Endocrinol. Metab. 75, 1060-1065 (1992).
9. Harel, Z. et al. Bone mineral density in postmenarchal adolescent girls in the United States: associated biopsychosocial variables and bone turnover markers. J. Adolesc. Health 40, 44-53 (2007).
10. Sabatier, J. P. et al. Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10-24 years of age. Osteoporos. Int. 6, 141-148 (1996).
11. Riggs, B. L., Khosla, S. & Melton, L. J. 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23, 279-302 (2002).
12. Cara, J., Rosenfield, R. & Furlanetto, R. A longitudinal study of the relationship of plasma somatomedin-C concentration to the pubertal growth spurt. Am. J. Dis. Child. 141, 562-564 (1987).
13. Misra, M., Cord, J., Prabhakaran, R., Miller, K. K. & Klibanski, A. Growth hormone suppression after an oral glucose load in children. J. Clin. Endocrinol. Metab. 92, 4623-4629 (2007).
14. Russell, M., Breggia, A., Mendes, N., Klibanski, A. & Misra, M. Growth hormone is positively associated with surrogate markers of bone turnover during puberty. Clin. Endocrinol. (Oxf.) 75, 482-488 (2011).
15. Riggs, B. L. The mechanisms of estrogen regulation of bone resorption. J. Clin. Invest. 106, 1203-1204 (2000).
16. Wang, Q. et al. Differential effects of sex hormones on peri- and endocortical bone surfaces in pubertal girls. J. Clin. Endocrinol. Metab. 91, 277-282 (2006).
17. Eastell, R. Role of oestrogen in the regulation of bone turnover at the menarche. J. Endocrinol. 185, 223-234 (2005).
18. Leder, B. Z., LeBlanc, K. M., Schoenfeld, D. A., Eastell, R. & Finkelstein, J. S. Differential effects of androgens and estrogens on bone turnover in normal men. J. Clin. Endocrinol. Metab. 88, 204-210 (2003).
19. Michael, H., Härkönen, P. L., Väänänen, H. K. & Hentunen, T. A. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J. Bone Miner. Res. 20, 2224-2232 (2005).
20. Falahati-Nini, A. et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 106, 1553-1560 (2000).
21. Gallagher, J. C., Riggs, B. L. & DeLuca, H. F. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 51, 1359-1364 (1980).
22. Ash, S. L. & Goldin, B. R. Effects of age and estrogen on renal vitamin D metabolism in the female rat. Am. J. Clin. Nutr. 47, 694-699 (1988).
23. Hagenfeldt, Y., Linde, K., Sjöberg, H. E., Zumkeller, W. & Arver, S. Testosterone increases serum 1, 25-dihydroxyvitamin D and insulin-like growth factor-I in hypogonadal men. Int. J. Androl. 15, 93-102 (1992).
24. Wikström, A. M., Bay, K., Hero, M., Andersson, A. M. & Dunkel, L. Serum insulin-like factor 3 levels during puberty in healthy boys and boys with Klinefelter syndrome. J. Clin. Endocrinol. Metab. 91, 4705-4708 (2006).
25. Pepe, A. et al. INSL3 plays a role in the balance between bone formation and resorption. Ann. NY Acad. Sci. 1160, 219-220 (2009).
26. Ferlin, A. et al. Mutations in the insulin-like factor 3 receptor are associated with osteoporosis. J. Bone Miner. Res. 23, 683-693 (2008).
27. Foresta, C. et al. Bone mineral density and testicular failure: evidence for a role of vitamin D 25-hydroxylase in human testis. J. Clin. Endocrinol. Metab. 96, E646-E652 (2011).
28. Oury, F. et al. Endocrine regulation of male fertility by the skeleton. Cell 144, 796-809 (2011).
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. revised: DSM-III-R (American Psychiatric Association, Washington DC, 1987).
30. Grinspoon, S. et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann. Intern. Med. 133, 790-794 (2000).
31. Estour, B. et al. Hormonal profile heterogeneity and short-term physical risk in restrictive anorexia nervosa. J. Clin. Endocrinol. Metab. 95, 2203-2210 (2010).
32. Grinspoon, S. et al. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J. Clin. Endocrinol. Metab. 81, 3864-3870 (1996).
33. Soyka, L. A. et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 87, 4177-4185 (2002).
34. Misra, M. et al. Weight gain and restoration of menses as predictors of bone mineral density change in adolescent girls with anorexia nervosa-1. J. Clin. Endocrinol. Metab. 93, 1231-1237 (2008).
35. Misra, M. et al. Bone metabolism in adolescent boys with anorexia nervosa. J. Clin. Endocrinol. Metab. 93, 3029-3036 (2008).
36. Misra, M. et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 88, 3816-3822 (2003).
37. Lawson, E. A. et al. Hormone predictors of abnormal bone microarchitecture in women with anorexia nervosa. Bone 46, 458-463 (2010).
38. Milos, G. et al. Cortical and trabecular bone density and structure in anorexia nervosa. Osteoporos. Int. 16, 783-790 (2005).
39. Bredella, M. A. et al. Distal radius in adolescent girls with anorexia nervosa: trabecular structure analysis with high-resolution flat-panel volume CT. Radiology 249, 938-946 (2008).
40. Vestergaard, P. et al. Fractures in patients with anorexia nervosa, bulimia nervosa, and other eating disorders-a nationwide register study. Int. J. Eat. Disord. 32, 301-308 (2002).
41. Lucas, A. R., Melton, L. J. 3rd, Crowson, C. S. & O'Fallon, W. M. Long-term fracture risk among women with anorexia nervosa: a population-based cohort study. Mayo Clin. Proc. 74, 972-977 (1999).
42. Miller, K. K. et al. Determinants of skeletal loss and recovery in anorexia nervosa. J. Clin. Endocrinol. Metab. 91, 2931-2937 (2006).
43. Misra, M. et al. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 92, 2046-2052 (2007).
44. Misra, M. et al. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 88, 5615-5623 (2003).
45. Soyka, L. A., Grinspoon, S., Levitsky, L. L., Herzog, D. B. & Klibanski, A. The effects of anorexia nervosa on bone metabolism in female adolescents. J. Clin. Endocrinol. Metab. 84, 4489-4496 (1999).
46. Misra, M. et al. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. J. Clin. Endocrinol. Metab. 89, 4972-4980 (2004).
47. Wojcik, M. H. et al. Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa. Bone 46, 796-800 (2010).
48. Misra, M. et al. Elevated peptide YY levels in adolescent girls with anorexia nervosa. J. Clin. Endocrinol. Metab. 91, 1027-1033 (2006).
49. Utz, A. L. et al. Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. Bone 43, 135-139 (2008).
50. Gordon, C. M. et al. Physiologic regulators of bone turnover in young women with anorexia nervosa. J. Pediatr. 141, 64-70 (2002).
51. Misra, M. et al. Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J. Bone Miner. Res. 26, 2430-2438 (2011).
52. Misra, M. et al. Nutrient intake in community-dwelling adolescent girls with anorexia nervosa and in healthy adolescents. Am. J. Clin. Nutr. 84, 698-706 (2006).
53. Haagensen, A. L., Feldman, H. A., Ringelheim, J. & Gordon, C. M. Low prevalence of vitamin D deficiency among adolescents with anorexia nervosa. Osteoporos. Int. 19, 289-294 (2008).
54. Golden, N. H. et al. The effect of estrogen-progestin treatment on bone mineral density in anorexia nervosa. J. Pediatr. Adolesc. Gynecol. 15, 135-143 (2002).
55. Strokosch, G. R., Friedman, A. J., Wu, S. C. & Kamin, M. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in adolescent females with anorexia nervosa: a double-blind, placebo-controlled study. J. Adolesc. Health 39, 819-827 (2006).
56. Ho, K. K. & Weissberger, A. J. Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J. Bone Miner. Res. 7, 821-827 (1992).
57. Weissberger, A. J., Ho, K. K. & Lazarus, L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J. Clin. Endocrinol. Metab. 72, 374-381 (1991).
58. Miller, K. K. et al. Androgens in women with anorexia nervosa and normal-weight women with hypothalamic amenorrhea. J. Clin. Endocrinol. Metab. 92, 1334-1339 (2007).
59. Cuttler, L., Van Vliet, G., Conte, F. A., Kaplan, S. L. & Grumbach, M. M. Somatomedin-C levels in children and adolescents with gonadal dysgenesis: differences from age-matched normal females and effect of chronic estrogen replacement therapy. J. Clin. Endocrinol. Metab. 60, 1087-1092 (1985).
60. Nabhan, Z. M., Dimeglio, L. A., Qi, R., Perkins, S. M. & Eugster, E. A. Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. J. Clin. Endocrinol. Metab. 94, 2009-2014 (2009).
61. Taboada, M. et al. Pharmacokinetics and pharmacodynamics of oral and transdermal 17β estradiol in girls with turner syndrome. J. Clin. Endocrinol. Metab. 96, 3502-3510 (2011).
62. Fazeli, P. et al. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 95, 4889-4897 (2010).
63. Misra, M. et al. Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa. Bone 45, 493-498 (2009).
64. Grinspoon, S., Thomas, L., Miller, K., Herzog, D. & Klibanski, A. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J. Clin. Endocrinol. Metab. 87, 2883-2891 (2002).
65. Gordon, C. M. et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J. Clin. Endocrinol. Metab. 87, 4935-4941 (2002).
66. Golden, N. H. et al. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 90, 3179-3185 (2005).
67. Miller, K. K. et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 2081-2088 (2011).
68. Nichols, J. F., Rauh, M. J., Lawson, M. J., Ji, M. & Barkai, H. S. Prevalence of the female athlete triad syndrome among high school athletes. Arch. Pediatr. Adolesc. Med. 160, 137-142 (2006).
69. Loucks, A. B. & Horvath, S. M. Athletic amenorrhea: a review. Med. Sci. Sports Exerc. 17, 56-72 (1985).
70. Otis, C. L. Exercise-associated amenorrhea. Clin. Sports Med. 11, 351-362 (1992).
71. Shangold, M., Rebar, R. W., Wentz, A. C. & Schiff, I. Evaluation and management of menstrual dysfunction in athletes. JAMA 263, 1665-1669 (1990).
72. Sanborn, C. F., Martin, B. J. & Wagner, W. W. Jr. Is athletic amenorrhea specific to runners? Am. J. Obstet. Gynecol. 143, 859-861 (1982).
73. Robinson, T. L. et al. Gymnasts exhibit higher bone mass than runners despite similar prevalence of amenorrhea and oligomenorrhea. J. Bone Miner. Res. 10, 26-35 (1995).
74. Christo, K. et al. Bone metabolism in adolescent athletes with amenorrhea, athletes with eumenorrhea, and control subjects. Pediatrics 121, 1127-1136 (2008).
75. Cobb, K. et al. Disordered eating, menstrual irregularity, and bone mineral density in female runners. Med. Sci. Sports Exerc. 35, 711-719 (2003).
76. Ihle, R. & Loucks, A. B. Dose-response relationships between energy availability and bone turnover in young exercising women. J. Bone Miner. Res. 19, 1231-1240 (2004).
77. Russell, M. et al. Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls. Bone 45, 104-109 (2009).
78. Castelo-Branco, C. et al. Bone mineral density in young, hypothalamic oligoamenorrheic women treated with oral contraceptives. J. Reprod. Med. 46, 875-879 (2001).
79. Hergenroeder, A. C. et al. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months. Am. J. Obstet. Gynecol. 176, 1017-1025 (1997).
80. Gibson, J. H., Mitchell, A., Reeve, J. & Harries, M. G. Treatment of reduced bone mineral density in athletic amenorrhea: a pilot study. Osteoporos. Int. 10, 284-289 (1999).
81. Burr, D. B. et al. Exercise and oral contraceptive use suppress the normal age-related increase in bone mass and strength of the femoral neck in women 18-31 years of age. Bone 27, 855-863 (2000).
82. Hartard, M. et al. Age at first oral contraceptive use as a major determinant of vertebral bone mass in female endurance athletes. Bone 35, 836-841 (2004).
83. Nattiv, A. et al. American College of Sports Medicine position stand. The female athlete triad. Med. Sci. Sports Exerc. 39, 1867-1882 (2007).
84. Ishizaka, K., Suzuki, M., Kageyama, Y., Kihara, K. & Yoshida, K. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement. Asian J. Androl. 4, 117-121 (2002).
85. Legrand, E. et al. Trabecular bone microarchitecture is related to the number of risk factors and etiology in osteoporotic men. Microsc. Res. Tech. 70, 952-959 (2007).
86. Lubushitzky, R. et al. Quantitative bone SPECT in young males with delayed puberty and hypogonadism: implications for treatment of low bone mineral density. J. Nucl. Med. 39, 104-107 (1998).
87. Okinaga, H., Matsuno, A. & Okazaki, R. High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions. Endocr. J. 52, 751-756 (2005).
88. Mazziotti, G. et al. Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary 11, 55-61 (2008).
89. Wüster, C. et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J. Bone Miner. Res. 16, 398-405 (2001).
90. Kosowicz, J., El Ali, Z., Ziemnicka, K. & Sowinski, J. Abnormalities in bone mineral density distribution and bone scintigraphy in patients with childhood onset hypopituitarism. J. Clin. Densitom. 10, 332-339 (2007).
91. Miller, K. K. et al. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 91, 1683-1690 (2006).
92. Ragnarsson, O., Nyström, H. F. & Johannsson, G. Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism. Clin. Endocrinol. (Oxf.) 76, 246-252 (2012).
93. Colao, A. et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin. Endocrinol. (Oxf.) 52, 319-327 (2000).
94. Galli-Tsinopoulou, A., Nousia-Arvanitakis, S., Mitsiakos, G., Karamouzis, M. & Dimitriadis, A. Osteopenia in children and adolescents with hyperprolactinemia. J. Pediatr. Endocrinol. Metab. 13, 439-441 (2000).
95. Ciccarelli, E. et al. Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women. Clin. Endocrinol. (Oxf.) 28, 1-6 (1988).
96. Klibanski, A., Biller, B. M., Rosenthal, D. I., Schoenfeld, D. A. & Saxe, V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J. Clin. Endocrinol. Metab. 67, 124-130 (1988).
97. Naliato, E. C., Farias, M. L. & Violante, A. H. Prolactinomas and bone mineral density in men [Portuguese]. Arq. Bras. Endocrinol. Metabol. 49, 183-195 (2005).
98. Naliato, E. C. et al. Bone density in women with prolactinoma treated with dopamine agonists. Pituitary 11, 21-28 (2008).
99. Seriwatanachai, D. et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor êB ligand/osteoprotegerin ratio. Bone 42, 535-546 (2008).
100. Klibanski, A. & Greenspan, S. L. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 315, 542-546 (1986).
101. Schlaff, W. D., Carson, S. A., Luciano, A., Ross, D. & Bergqvist, A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil. Steril. 85, 314-325 (2006).
102. Hornstein, M. D., Surrey, E. S., Weisberg, G. W. & Casino, L. A. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet. Gynecol. 91, 16-24 (1998).
103. Mitwally, M. F., Gotlieb, L. & Casper, R. F. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 9, 236-241 (2002).
104. Ripps, B. A., VanGilder, K., Minhas, B., Welford, M. & Mamish, Z. Alendronate for the prevention of bone mineral loss during gonadotropin- releasing hormone agonist therapy. J. Reprod. Med. 48, 761-766 (2003).
105. Cromer, B. A. et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J. Adolesc. Health 35, 434-441 (2004).
106. Scholes, D., LaCroix, A. Z., Ichikawa, L. E., Barlow, W. E. & Ott, S. M. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch. Pediatr. Adolesc. Med. 159, 139-144 (2005).
107. Walsh, J. S., Eastell, R. & Peel, N. F. Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J. Clin. Endocrinol. Metab. 93, 1317-1323 (2008).
108. Cromer, B. A. et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24-month prospective study. Fertil. Steril. 90, 2060-2067 (2008).
109. Kaunitz, A. M., Miller, P. D., Rice, V. M., Ross, D. & McClung, M. R. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 74, 90-99 (2006).
110. Kaunitz, A. M., Arias, R. & McClung, M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 77, 67-76 (2008).
111. Popat, V. B. et al. Bone mineral density in estrogen-deficient young women. J. Clin. Endocrinol. Metab. 94, 2277-2283 (2009).
112. Uygur, D. et al. Bone loss in young women with premature ovarian failure. Arch. Gynecol. Obstet. 273, 17-19 (2005).
113. Leite-Silva, P., Bedone, A., Pinto-Neto, A. M., Costa, J. V. & Costa-Paiva, L. Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure. Arch. Gynecol. Obstet. 280, 177-181 (2009).
114. Allen, E. G. et al. Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum. Reprod. 22, 2142-2152 (2007).
115. Bakalov, V. K. et al. Selective reduction in cortical bone mineral density in turner syndrome independent of ovarian hormone deficiency. J. Clin. Endocrinol. Metab. 88, 5717-5722 (2003).
116. Costa, A. M. et al. Bone mineralization in Turner syndrome: a transverse study of the determinant factors in 58 patients. J. Bone Miner. Metab. 20, 294-297 (2002).
117. Gravholt, C. H. et al. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study. J. Clin. Endocrinol. Metab. 87, 2798-2808 (2002).
118. Bakalov, V. K. et al. Bone mineral density and fractures in Turner syndrome. Am. J. Med. 115, 259-264 (2003).
119. Holroyd, C. R. et al. Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome. Osteoporos. Int. 21, 2093-2099 (2010).
120. Buzi, F. et al. Serum osteoprotegerin and receptor activator of nuclear factors êB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin. Endocrinol. (Oxf.) 60, 87-91 (2004).
121. Gravholt, C. H. et al. Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey. Clin. Endocrinol. (Oxf.) 59, 89-96 (2003).
122. Nissen, N. et al. Disproportional geometry of the proximal femur in patients with Turner syndrome: a cross-sectional study. Clin. Endocrinol. (Oxf.) 67, 897-903 (2007).
123. Landin-Wilhelmsen, K., Bryman, I., Windh, M. & Wilhelmsen, L. Osteoporosis and fractures in Turner syndrome-importance of growth promoting and oestrogen therapy. Clin. Endocrinol. (Oxf.) 51, 497-502 (1999).
124. Högler, W. et al. Importance of estrogen on bone health in turner syndrome: a cross-sectional and longitudinal study using dual-energy x-ray absorptiometry. J. Clin. Endocrinol. Metab. 89, 193-199 (2004).
125. Sass, T. C. et al. A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial. Clin. Endocrinol. (Oxf.) 52, 531-536 (2000).
126. Molina, J. R., Barton, D. L. & Loprinzi, C. L. Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf. 28, 401-416 (2005).
127. Hadji, P., Ziller, M., Maskow, C., Albert, U. & Kalder, M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur. J. Cancer 45, 3205-3212 (2009).
128. Saarto, T., Blomqvist, C., Rissanen, P., Auvinen, A. & Elomaa, I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br. J. Cancer 75, 301-305 (1997).
129. Bruning, P. F. et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br. J. Cancer 61, 308-310 (1990).
130. Headley, J. A., Theriault, R. L., LeBlanc, A. D., Vassilopoulou-Sellin, R. & Hortobagyi, G. N. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest. 16, 6-11 (1998).
131. Powles, T. J. et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J. Natl Cancer Inst. 90, 704-708 (1998).
132. Tham, Y. L. et al. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause. J. Support. Oncol. 4, 295-298 (2006).
133. Davies, J. H., Evans, B. A., Jenney, M. E. & Gregory, J. W. In vitro effects of combination chemotherapy on osteoblasts: implications for osteopenia in childhood malignancy. Bone 31, 319-326 (2002).
134. Vehmanen, L., Elomaa, I., Blomqvist, C. & Saarto, T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J. Clin. Oncol. 24, 675-680 (2006).
135. Pereyra Pacheco, B. et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol. Oncol. 81, 391-397 (2001).
136. Blumenfeld, Z., Dann, E., Avivi, I., Epelbaum, R. & Rowe, J. M. Fertility after treatment for Hodgkin's disease. Ann. Oncol. 13 (Suppl. 1), 138-147 (2002).
137. Mardesic, T. et al. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. Eur. J. Gynaecol. Oncol. 25, 90-92 (2004).
138. Recchia, F. et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs 13, 417-424 (2002).
139. Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9, 840-849 (2008).
140. Gnant, M. F. et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 25, 820-828 (2007).
141. Cumber, P. M. & Whittaker, J. A. Ovarian failure after total body irradiation. BMJ 300, 464 (1990).
142. Kondo, H. et al. Total-body irradiation of postpubertal mice with 137Cs acutely compromises the microarchitecture of cancellous bone and increases osteoclasts. Radiat. Res. 171, 283-289 (2009).
143. Bakker, B. et al. Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies. Eur. J. Pediatr. 159, 31-37 (2000).
144. Sarafoglou, K., Boulad, F., Gillio, A. & Sklar, C. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J. Pediatr. 130, 210-216 (1997).
145. Castelo-Branco, C. et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 23, 307-312 (1996).